



Divi's Laboratories Limited

Date: November 07, 2025

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
Mumbai – 400 051

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400 001

Trading Symbol: **DIVISLAB**

Scrip Code: **532488**

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on November 07, 2025

Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Further to our intimation dated October 27, 2025, we would like to inform that the Board of Directors of the Company at its meeting held on November 07, 2025, has approved, inter alia, the following items of business:

Financial Results

Approved the statement of unaudited financial results, standalone and consolidated, for the quarter and half year ended September 30, 2025. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:

1. Statement of standalone unaudited financial results for the quarter and half year ended September 30, 2025 and Limited Review Report of the Statutory Auditors thereon.
2. Statement of consolidated unaudited financial results for the quarter and half year ended September 30, 2025 and Limited Review Report of the Statutory Auditors thereon.
3. Press release on the financial results of the Company.

Changes in Senior Management Personnel

Approved change in designation of Mr. Nimmagadda Venkata Anirudh as President (Nutraceuticals) and Senior Management Personnel of the Company with effect from November 07, 2025, as recommended by the Nomination and Remuneration Committee.

The particulars in relation to the said changes in Senior Management Personnel as required pursuant to SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 November 11, 2024, is enclosed as **Annexure – I**.



Divi's Laboratories Limited

The Board meeting commenced at 10.30 Hrs and concluded at 11.45 Hrs.

This is for your information and records.

Thanking you,

Yours faithfully,

For Divi's Laboratories Limited

M. Satish Choudhury

Company Secretary & Compliance Officer



Divi's Laboratories Limited

Annexure-I

Name	Mr. Nimmagadda Venkata Anirudh
Reason for change	Mr. Anirudh is designated as President (Nutraceuticals) and Senior Management Personnel with effective from November 07, 2025. He will be heading the entire nutraceutical business of the Company and will be reporting directly to the Chief Executive Officer of the Company.
Date of Appointment and term of appointment	November 07, 2025. Term of appointment: Full-time employment.
Brief Profile (in case of appointment)	Mr. Anirudh studied B.E. Mechanical Engineering and has done certification programmes on Strategic Marketing from Harvard University in Boston, on Investments from Indian Institute of Management in Ahmedabad, and on Family Office Management and Business Management from Jamnalal Bajaj Institute of Management Studies in Mumbai. He joined Divi's Laboratories Limited in the year 2014 as the Relationship Manager for all the customers in the US & Canada region. Post his role as Relationship Manager – USA, he was tasked with handling the Indian customers manufacturing the finished dose formulations for the global markets along with the MNC customers that Divi's was working with on the generic side of the business. In September 2022, he was promoted as Head of Nutraceuticals. In his role, he was assigned to maximize the sales potential for each of the nutraceutical ingredients, identification of new ingredients to the Company's portfolio, improve operational efficiencies, optimise raw material procurement and oversee the subsidiaries operations in USA and Switzerland.
Disclosure of relationship between directors	Mr. Anirudh is son of Mr. N.V. Ramana, Executive Director of the Company.

DIVI'S LABORATORIES LIMITED

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025**

(Rs. in Crores)

S. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	Revenue from operations	2660	2357	2302	5017	4365	9198
	Other income	146	119	105	265	183	352
	Total income	2806	2476	2407	5282	4548	9550
2	Expenses						
	a) Cost of materials consumed	907	989	953	1896	1835	3760
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	144	(72)	1	72	(55)	(83)
	d) Employee benefits expense	344	330	296	674	581	1210
	e) Depreciation and amortisation expense	113	112	98	225	195	401
	f) Finance costs	8	3	1	11	1	1
	g) Other expenses	370	367	323	737	653	1332
	Total expenses	1886	1729	1672	3615	3210	6621
3	Profit before exceptional Items and tax (1-2)	920	747	735	1667	1338	2929
4	Exceptional items	-	-	-	-	-	-
5	Profit before tax (3-4)	920	747	735	1667	1338	2929
6	Tax expense						
	a) Current tax	220	191	218	411	396	793
	b) Deferred tax	4	(1)	(1)	3	(6)	(73)
	Total tax expense	224	190	217	414	390	720
7	Profit for the period/year (5-6)	696	557	518	1253	948	2209
8	Other comprehensive income:						
	Items that will not be reclassified to Profit or Loss:						
	(i) Gain/(Loss) on Remeasurement of post-employment benefit obligation	-*	(1)	-*	(1)	(1)	(3)
	(ii) Income tax relating to the above	-*	-*	-*	-*	-*	1
	Total other comprehensive income (i+ii)	-*	(1)	-*	(1)	(1)	(2)
9	Total comprehensive income for the period/year (7+8)	696	556	518	1252	947	2207
10	Paid-up Equity Share Capital (Face Value: Rs. 2/- per share)	53	53	53	53	53	53
11	Other equity excluding revaluation reserve						14842
12	Earnings per Share # (Face Value: Rs. 2/- per share) (not annualized)						
	a) Basic (Rs.)	26.24	20.95	19.51	47.19	35.69	83.20
	b) Diluted (Rs.)	26.24	20.95	19.51	47.19	35.69	83.20

#Earnings per share calculated on actual amount of profit after tax in rupees

* Amount is below the rounding off norms adopted by the company.



Kai Di



DIVI'S LABORATORIES LIMITED

**STATEMENT OF STANDALONE UNAUDITED ASSETS AND LIABILITIES
AS AT 30TH SEPTEMBER, 2025**

(Rs. in Crores)

S. No.	Particulars	As at	
		30.09.2025	31.03.2025
		(Unaudited)	(Audited)
A	ASSETS		
1	Non-current assets		
	Property, plant and equipment	5671	5436
	Capital work-in-progress	2030	1022
	Intangible assets	4	4
	Financial assets		
	a) Investments	74	72
	b) Other financial assets	65	62
	Income tax assets (net)	1	1
	Other non-current assets	452	248
	Sub-total: Non-current assets	8297	6845
2	Current assets		
	Inventories	3240	3033
	Financial assets		
	a) Trade receivables	2773	2855
	b) Cash and cash equivalents	61	396
	c) Bank balances other than (b) above	3178	3300
	d) Other financial assets	8	16
	Income-tax assets (net)	14	12
	Other current assets	504	367
	Sub-total: Current assets	9778	9979
	TOTAL ASSETS	18075	16824
B	EQUITY AND LIABILITIES		
1	Equity		
	Equity Share Capital	53	53
	Other Equity	15298	14842
	Sub-total: Total Equity	15351	14895
2	Liabilities		
	Non-current liabilities		
	Financial liabilities		
	a) Other financial liabilities	274	-
	Other non-current liabilities	224	-
	Deferred tax liabilities (net)	512	509
	Sub-total: Non-current liabilities	1010	509
3	Current liabilities		
	Financial liabilities		
	a) Borrowings	89	2
	b) Trade payables		
	Total outstanding dues of micro and small enterprises	9	37
	Total outstanding dues other than above	1024	843
	c) Other financial liabilities	266	134
	Current tax liabilities (net)	45	-
	Other current liabilities	220	350
	Provisions	61	54
	Sub-total: Current liabilities	1714	1420
	Total Liabilities	2724	1929
	TOTAL EQUITY AND LIABILITIES	18075	16824



Kai Di



DIVI'S LABORATORIES LIMITED

**STATEMENT OF STANDALONE UNAUDITED CASH FLOWS FOR THE HALF YEAR ENDED
30th SEPTEMBER 2025**

(Rs. in Crores)

Particulars	For the Half year ended		For the year ended
	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)	31.03.2025 (Audited)
A. Cash flow from operating activities			
Profit before tax	1667	1338	2929
Adjustments for:			
Depreciation and amortisation expense	225	195	401
Unrealised foreign exchange (gain)/ loss	(44)	(14)	6
Interest income from financial assets at amortised cost	(157)	(152)	(295)
Change in fair value of investment in optionally convertible debentures	(2)	(3)	(1)
Gain on redemption of investments	-	-	(4)
Interest expense	5	.*	1
Provision for doubtful debts / (written back) including bad debts written off / (recovered)	2	1	1
Loss/(gain) on disposal / discard of property, plant and equipment and intangible assets	.*	4	4
Amortisation of government grants	.*	.*	.*
	1696	1369	3042
Change in operating assets and liabilities			
(Increase) /Decrease in trade receivables	150	18	(592)
(Increase) /Decrease in inventories	(207)	27	(48)
(Increase) /Decrease in other non-current assets	.*	-	-
(Increase) /Decrease in other non-current financial assets	(3)	1	(6)
(Increase) /Decrease in other current financial assets	8	(6)	(9)
(Increase) /Decrease in other current assets	(137)	(66)	(49)
Increase /(Decrease) in employee benefit obligation	6	3	7
Increase /(Decrease) in trade payables	147	16	82
Increase / (Decrease) in other non-current financial liabilities	260	-	-
Increase / (Decrease) in other non-current liabilities	224	-	-
Increase/ (Decrease) in other current financial liabilities	.*	-	-
Increase /(Decrease) in other current liabilities	(136)	(64)	41
Cash generated from operations	2008	1298	2468
Income taxes paid including withholding tax and net of refunds	(368)	(364)	(818)
Net cash inflow from operating activities	1640	934	1650
B. Cash flow from investing activities			
Payments for property, plant and equipment	(1544)	(662)	(1437)
Proceeds from sale of property, plant and equipment	3	-	.*
Proceeds from redemption of optionally convertible debentures	-	-	22
Interest received	158	152	295
Proceeds from withdrawal of deposits	2855	1002	3541
Investment in deposits	(2733)	(949)	(3224)
Net cash outflow from investing activities	(1261)	(457)	(803)



Handwritten signature



DIVI'S LABORATORIES LIMITED

STATEMENT OF STANDALONE UNAUDITED CASH FLOWS FOR THE HALF YEAR ENDED 30th SEPTEMBER 2025

(Rs. in Crores)

Particulars	For the Half year ended		For the year ended
	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)	31.03.2025 (Audited)
C. Cash flow from financing activities			
Proceeds /(repayment) of working capital loans (net)	83	5	-
Interest paid	(5)	(1)	(1)
Dividend paid to company's shareholders	(796)	(796)	(796)
Net cash outflow from financing activities	(718)	(792)	(797)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	(339)	(315)	50
Cash and cash equivalents at the beginning of the period/year	394	344	344
Cash and cash equivalents at end of the period/year	55	29	394
Reconciliation of cash and cash equivalents at the end of the period/ year			
Cash and cash equivalents as per Balance sheet	61	29	396
Overdraft facilities from bank	(6)	-	(2)
Balances as per Statement of cash flows	55	29	394

* Amount is below the rounding off norms adopted by the company.


Notes:

- The above Statement of Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2025, Statement of Standalone Unaudited Assets and Liabilities as at 30th September, 2025 and Statement of Standalone Unaudited Cash Flows for the half year ended 30th September, 2025 ('Standalone Statement') are prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. This Standalone Statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 07, 2025. The statutory auditors have carried out a limited review of this Standalone Statement and issued an unmodified report thereon.
- The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients and the same constitutes a single reportable business segment as per Ind AS 108.
- The Company does not have any discontinued operations and the profit for the period represents the profits from continuing operations only.
- Details of Forex gain are as given below:

(Rs. in Crores)

	Quarter ended			Half Year ended		Year ended
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
Forex gain	64	39	27	103	26	48

Forex gain has been included in other income.



For Divi's Laboratories Limited

Kiran S Divi

Dr. Kiran S Divi
Whole-time Director and
Chief Executive Officer



Price Waterhouse Chartered Accountants LLP

Review Report

To

The Board of Directors

M/s Divi's Laboratories Limited

Divi Towers, 1-72/23(P)/303,

Cyber Hills, Gachibowli,

Hyderabad, 500032

1. We have reviewed the standalone unaudited financial results of Divi's Laboratories Limited (the "Company") for the quarter ended September 30, 2025 and the year to date results for the period April 01, 2025 to September 30, 2025, which are included in the accompanying Statement of Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2025, the Statement of Standalone Unaudited Assets and Liabilities as on that date and the Statement of Standalone Unaudited Cash Flows for the half year ended on that date (the "Standalone Statement"). The Standalone Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. This Standalone Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Standalone Statement based on our review.
2. We conducted our review of the Standalone Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Standalone Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Standalone Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse Chartered Accountants LLP

Firm Registration Number: 012754N/N500016



N.K. Varadarajan

Partner

Membership Number: 90196

UDIN: 25090196BMRJSN8995

Place: Hyderabad

Date : November 07, 2025

Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block E1, Parcel - 4, Salarpuria
Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081
T: +91 (40) 44246740

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

DIVI'S LABORATORIES LIMITED

**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025**

(Rs. in Crores)

S. No	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	Revenue from operations	2715	2410	2338	5125	4456	9360
	Other income	145	119	106	264	184	352
	Total income	2860	2529	2444	5389	4640	9712
2	Expenses						
	a) Cost of materials consumed	937	1010	976	1947	1869	3821
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	136	(54)	(7)	82	(47)	(96)
	d) Employee benefits expense	354	340	304	694	596	1243
	e) Depreciation and amortisation expense	113	112	99	225	196	402
	f) Finance costs	8	3	1	11	1	2
	g) Other expenses	400	385	349	785	699	1424
	Total expenses	1948	1796	1722	3744	3314	6796
3	Profit before exceptional items and tax (1-2)	912	733	722	1645	1326	2916
4	Exceptional items	-	-	-	-	-	-
5	Profit before tax (3-4)	912	733	722	1645	1326	2916
6	Tax expense						
	a) Current tax	220	191	218	411	397	799
	b) Deferred tax	3	(3)	(6)	-*	(11)	(74)
	Total tax expense	223	188	212	411	386	725
7	Profit for the period/year (5-6)	689	545	510	1234	940	2191
8	Profit for the period/year attributable to:						
	Shareholders of the Company	689	545	510	1234	940	2191
	Non-Controlling Interest	-	-	-	-	-	-
9	Other Comprehensive Income:						
	a) Items that will not be reclassified to profit or loss:						
	i) Gain/(loss) on Remeasurement of post-employment benefit obligations	-*	(1)	-*	(1)	(1)	(3)
	ii) Income tax relating to the above	-*	-*	-*	-*	-*	1
	b) Items that will be reclassified to profit or loss:						
	i) Gain on exchange differences in translating the financial statements of foreign operations	5	4	2	9	4	6
	ii) Income tax relating to the above	(2)	-*	(1)	(2)	(1)	(1)
	Total other comprehensive income (a+b)	3	3	1	6	2	3
10	Total other comprehensive income for the period/ year attributable to:						
	Shareholders of the Company	3	3	1	6	2	3
	Non-Controlling Interest	-	-	-	-	-	-
11	Total comprehensive income for the period/year (7+9)	692	548	511	1240	942	2194
12	Total comprehensive income for the period/ year attributable to:						
	Shareholders of the Company	692	548	511	1240	942	2194
	Non-Controlling Interest	-	-	-	-	-	-
13	Paid-up Equity Share Capital (Face Value: Rs. 2/- per share)	53	53	53	53	53	53
14	Other equity excluding revaluation reserve						14916
15	Earnings per Share # (Face Value: Rs. 2/- per share) (not annualized)						
	a) Basic (Rs.)	25.97	20.49	19.20	46.46	35.40	82.53
	b) Diluted (Rs.)	25.97	20.49	19.20	46.46	35.40	82.53

#Earnings per share calculated on actual amount of profit after tax in rupees

* Amount is below the rounding off norms adopted by the group.

Lain Di.



DIVI'S LABORATORIES LIMITED

**STATEMENT OF CONSOLIDATED UNAUDITED ASSETS AND LIABILITIES
AS AT 30TH SEPTEMBER, 2025**

(Rs. in Crores)

S. No.	Particulars	As at	
		30.09.2025	31.03.2025
		(Unaudited)	(Audited)
A	ASSETS		
1	Non-current assets		
	Property, plant and equipment	5672	5437
	Right of use assets	2	1
	Capital work-in-progress	2030	1022
	Intangible assets	4	4
	Financial assets		
	a) Investments	67	65
	b) Other financial assets	65	62
	Income tax assets (net)	4	1
	Deferred tax asset	12	11
	Other non-current assets	452	248
	Sub-total: Non-current assets	8308	6851
2	Current assets		
	Inventories	3433	3236
	Financial assets		
	a) Trade receivables	2614	2731
	b) Cash and cash equivalents	83	415
	c) Bank balances other than (b) above	3178	3300
	d) Other financial assets	8	16
	Income-tax assets (net)	14	13
	Other current assets	513	370
	Sub-total: Current assets	9843	10081
	TOTAL ASSETS	18151	16932
B	EQUITY AND LIABILITIES		
1	Equity		
	Equity Share Capital	53	53
	Other Equity	15360	14916
	Sub-total: Total Equity	15413	14969
2	Liabilities		
	Non-current liabilities		
	Financial liabilities		
	a) Lease liabilities	-*	2
	b) Other financial liabilities	274	-
	Other non-current liabilities	224	-
	Deferred tax liabilities (net)	512	509
	Sub-total: Non-current liabilities	1010	511
3	Current liabilities		
	Financial liabilities		
	a) Borrowings	89	2
	b) Lease liabilities	1	-*
	c) Trade payables		
	Total outstanding dues of micro and small enterprises	9	37
	Total outstanding dues other than above	1031	873
	d) Other financial liabilities	267	134
	Current tax liabilities (net)	45	-
	Other current liabilities	224	352
	Provisions	62	54
	Sub-total: Current liabilities	1728	1452
	Total Liabilities	2738	1963
	TOTAL EQUITY AND LIABILITIES	18151	16932

* Amount is below the rounding off norms adopted by the group.



San Di.



DIVI'S LABORATORIES LIMITED

**STATEMENT OF CONSOLIDATED UNAUDITED CASH FLOWS FOR THE HALF YEAR ENDED
30th SEPTEMBER 2025**

(Rs. in Crores)

Particulars	For the Half year ended		For the year ended
	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)	31.03.2025 (Audited)
A. Cash flow from operating activities			
Profit before tax	1645	1326	2916
Adjustments for:			
Depreciation and amortisation expense	225	196	402
Unrealised foreign exchange (gain)/ loss	(40)	(11)	9
Interest income from financial assets at amortised cost	(157)	(152)	(295)
Change in fair value of investment in optionally convertible debentures	(2)	(3)	(1)
Gain on redemption of investments	-	-	(4)
Interest expense	5	1	2
Provision for doubtful debts / (written back) including bad debts written off / (recovered)	1	-	(2)
Loss/(gain) on disposal / discard of property, plant and equipment and intangible assets	_*	4	4
Amortisation of government grants	_*	_*	_*
	1677	1361	3031
Change in operating assets and liabilities			
(Increase) /Decrease in trade receivables	188	(3)	(582)
(Increase) /Decrease in inventories	(197)	39	(52)
(Increase) /Decrease in other non-current assets	_*	-	-
(Increase) /Decrease in other non-current financial assets	(3)	(6)	(6)
(Increase) /Decrease in other current financial assets	8	1	(9)
(Increase) /Decrease in other current assets	(143)	(66)	(50)
Increase /(Decrease) in employee benefit obligation	7	3	7
Increase /(Decrease) in trade payables	124	32	95
Increase / (Decrease) in other non-current financial liabilities	260	-	-
Increase / (Decrease) in other non-current liabilities	224	-	-
Increase/ (Decrease) in other current financial liabilities	_*	-	-
Increase /(Decrease) in other current liabilities	(133)	(63)	43
Cash generated from operations	2012	1298	2447
Income taxes paid including withholding tax and net of refunds	(367)	(372)	(824)
Net cash inflow from operating activities	1645	926	1653
B. Cash flow from investing activities			
Payments for property, plant and equipment	(1544)	(664)	(1438)
Proceeds from sale of property, plant and equipment	3	-	_*
Proceeds from redemption of optionally convertible debentures	-	-	22
Interest received	158	152	295
Proceeds from withdrawal of deposits	2855	1002	3541
Investment in deposits	(2733)	(949)	(3224)
Net cash outflow from investing activities	(1261)	(459)	(804)



Handwritten signature in blue ink.



DIVI'S LABORATORIES LIMITED

**STATEMENT OF CONSOLIDATED UNAUDITED CASH FLOWS FOR THE HALF YEAR ENDED
30th SEPTEMBER 2025**

(Rs. in Crores)

Particulars	For the Half year ended		For the year ended
	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)	31.03.2025 (Audited)
C. Cash flow from financing activities			
Principal element of lease liabilities	(2)	-*	(1)
Proceeds /(repayment) of working capital loans (net)	83	5	-
Interest paid	(5)	(1)	(2)
Dividend paid to company's shareholders	(796)	(796)	(796)
Net cash outflow from financing activities	(720)	(792)	(799)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	(336)	(325)	50
Cash and cash equivalents at the beginning of the period/year	413	363	363
Cash and cash equivalents at end of the period/year	77	38	413
Reconciliation of cash and cash equivalents at the end of the period/ year			
Cash and cash equivalents as per Balance sheet	83	38	415
Overdraft facilities from bank	(6)	-	(2)
Balances as per Statement of cash flows	77	38	413

* Amount is below the rounding off norms adopted by the group.


Notes:

1. The above Statement of Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2025, Statement of Consolidated Unaudited Assets and Liabilities as at 30th September, 2025 and Statement of Consolidated Unaudited Cash Flows for the half year ended 30th September, 2025 ('Consolidated Statement') are prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. This Consolidated Statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 07, 2025. The statutory auditors have carried out a limited review of this Consolidated Statement and issued an unmodified report thereon.
2. The Consolidated Unaudited Financial Results include the financial results of Divi's Laboratories Limited and its two subsidiaries Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG (Referred as the "Group")
3. The Group is engaged in the manufacture of Active Pharmaceutical ingredients, intermediates, and nutraceutical ingredients and the same constitutes single reportable business segment as per Ind AS 108.
4. The Group does not have any discontinued operations and the profit for the period represents the profits from continuing operations only.
5. Details of Forex gain are as given below:

(Rs. in Crores)

	Quarter ended			Half Year ended		Year ended
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
Forex gain	63	39	29	102	28	48

Forex gain has been included in other income.



For Divi's Laboratories Limited

Kiran S Divi
Dr. Kiran S Divi
 Whole-time Director and
 Chief Executive Officer



Price Waterhouse Chartered Accountants LLP

Review Report

To
The Board of Directors
M/s Divi's Laboratories Limited
Divi Towers, 1-72/23(P)/303,
Cyber Hills, Gachibowli,
Hyderabad, 500032

1. We have reviewed the consolidated unaudited financial results of Divi's Laboratories Limited (the "Parent") and its subsidiaries (the parent and its subsidiaries hereinafter referred to as the "Group") (refer Note 2 on the Consolidated Statement) for the quarter ended September 30, 2025 and the year to date results for the period April 01, 2025 to September 30, 2025 which are included in the accompanying Statement of Consolidated Unaudited Financial results for the quarter and half year ended September 30, 2025, the Statement of Consolidated Unaudited Assets and Liabilities as on that date and the Statement of Consolidated Unaudited Cash Flows for the half year ended on that date (the "Consolidated Statement"). The Consolidated Statement is being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"), which has been initialled by us for identification purposes.
2. This Consolidated Statement, which is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Consolidated Statement based on our review.
3. We conducted our review of the Consolidated Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Consolidated Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Consolidated Statement includes the results of the following entities:
 - a) Divi's Laboratories (USA) Inc.
 - b) Divi's Laboratories Europe AG



Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block E1, Parcel - 4, Salarpuria
Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081
T: +91 (40) 44246740

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110002


Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N).

Price Waterhouse Chartered Accountants LLP

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Consolidated Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results includes the interim financial information/ financial results of 2 subsidiaries which have not been reviewed/audited by their auditors, whose interim financial information/ financial results reflect total assets of Rs. 527 crores and net assets of Rs. 132 crores as at September 30, 2025 and total revenue of Rs. 184 crores and Rs. 387 crores, total net loss after tax of Rs. 5 crores and Rs. 7 crores and total comprehensive income / (loss) of Rs. (0.57) crores and Rs. 0.37 crores for the quarter ended September 30, 2025 and for the period from April 01, 2025 to September 30, 2025, respectively, and cash flows (net) of Rs. 3 crores for the period from April 01, 2025 to September 30, 2025, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial information / financial results are not material to the Group.

Our conclusion on the Consolidated Statement is not modified in respect of the above matter.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



N.K. Varadarajan

Partner

Membership Number: 90196

UDIN: 25090196BMRJSO8929

Place: Hyderabad

Date : November 07, 2025



DIVI'S LABORATORIES LIMITED

CIN: L24110TG1990PLC011854

Registered Office: 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, India, Phone: +91 40 66966300, email: cs@divislabs.com, website: www.divislabs.com

PRESS RELEASE DATED NOVEMBER 07, 2025

Divi's Laboratories earns a Consolidated Total Income of ₹ 2860 crores for Q2 of FY26

Consolidated Financial Results

For the quarter ended 30th September 2025

Divi's Laboratories has earned a consolidated total income ₹ 2860 crores for the quarter ended 30th September 2025 as against a consolidated total income of ₹ 2444 crores for the corresponding quarter of the previous year. Profit before tax (PBT) for the quarter amounted to ₹ 912 crores as against a PBT of ₹ 722 crores for the corresponding quarter of the previous year. Profit after tax (PAT) for the quarter amounted to ₹ 689 Crores as against a PAT of ₹ 510 crores for the corresponding quarter of the previous year. For the current quarter, we have forex gain of ₹ 63 crores as against a gain of ₹29 crores during the corresponding quarter of the previous year.

For the Half year ended 30th September 2025

For the half year ended 30th September 2025 the Company earned a consolidated total income of ₹ 5389 crores as against a consolidated total income of ₹ 4640 crores during the corresponding half-year of the previous year. PBT for the current half year came to ₹ 1645 crores as against ₹ 1326 crores for the corresponding half year of the previous year. PAT for the current half year came to ₹ 1234 crores as against ₹ 940 crores for the corresponding half year of the previous year. For the current half-year we had a forex gain of ₹ 102 crores against a gain of ₹ 28 crores for the corresponding half year of the previous year.

Standalone Financial Results

On a standalone basis, the Company's earnings are given below:

Particulars	For the Quarter ended		For the half year ended	
	30-09-2025	30-09-2024	30-09-2025	30-09-2024
Total Income	2806	2407	5282	4548
PBT	920	735	1667	1338
Tax Expense	224	217	414	390
PAT	696	518	1253	948

₹ in crores

Forex Gain / (Loss):

Particulars of forex gain for the period, on standalone basis, are given below:

Particulars	For the Quarter ended		For the half year ended	
	30-09-2025	30-09-2024	30-09-2025	30-09-2024
Forex gain	64	27	103	26

₹ in crores